Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tiratrocol to treatment of coxsackie virus infection

A technology of coxsackie virus and tiratricol, which is applied in the directions of antiviral agents, medical preparations containing active ingredients, pharmaceutical formulations, etc., and can solve the problem that there is no coxsackie virus inhibited by tiratricol.

Active Publication Date: 2021-02-09
BEIJING UNIV OF CHEM TECH
View PDF10 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report on the inhibition of Coxsackie virus by tiratracol

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tiratrocol to treatment of coxsackie virus infection
  • Application of tiratrocol to treatment of coxsackie virus infection
  • Application of tiratrocol to treatment of coxsackie virus infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0050] Example 1. Screening of drug monomers with anti-Coxsackie virus activity from a drug library on the market

[0051] 1. Experimental method

[0052] 1. Cell culture and virus culture

[0053] The human kidney epithelial cell line 293T was obtained from the American Type Culture Collection (ATCC, CRL-3216TM) at 37°C, 5% CO 2 Under the condition of , cultured in DMEM medium (Gibco) containing 10% fetal bovine serum (FBS; Gibco Invitrogen).

[0054] Coxsackievirus A type 9 strain BUCT01 was propagated in 293T cells, and the virus titer was determined by RD cell (ATCC CCL-136) plaque assay. All infection experiments were performed in a Biosafety Level 2 (BLS-2) laboratory.

[0055] The listed drug library (product number L1000, including 2080 kinds of drugs already on the market) is a product of Shanghai Taosu Biochemical Technology Co., Ltd. The initial concentration of all drugs was 10 mM (millimole per liter).

[0056] 2. Explore whether B2M or FcRn is the receptor of ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of tiratrocol to treatment of coxsackie virus infection. The invention provides an application of the tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof or substances taking tiratropine or derivatives thereof or pharmaceutically acceptable salts thereof as active ingredients in any one of the following aspects: inhibiting coxsackie virus, treating diseases caused by coxsackie virus infection, and improving the symptoms caused by coxsackie virus infection. Based on a coxsackie virus drug screening model, an anti-coxsackie virusactive drug namely tiratrocol is screened from commercially available drugs. The tiratrocol has important clinical application value for treating diseases infected with the coxsackie virus.

Description

technical field [0001] The invention relates to the field of medicines, in particular to the application of teiratracol in the treatment of Coxsackie virus infection. Background technique [0002] Coxsackievirus (Coxsackievirus) is an enterovirus (enterovirus), which belongs to the Picornaviridae family and the genus Enterovirus. Its biological properties are similar to those of poliovirus, the diameter of the virion is 28nm, there is no envelope structure and the nucleic acid is single positive strand RNA. Coxsackie virus is a common virus that infects the human body through the respiratory tract and digestive tract. After infection, people will have cold symptoms such as fever, sneezing, and coughing. In severe cases, it can cause aseptic meningitis. According to the observation of the pathogenicity of the virus in the early stage of neonatal mouse infection, Coxsackie virus can be divided into two types: A and B. Among them, type A is more common in children and tends to...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/192A61P31/14
CPCA61K31/192A61P31/14
Inventor 童贻刚范华昊刘玉洁宋立华安小平贺哓琪娄福星陈杨桢韩可刘文丽王立钦胡运甲
Owner BEIJING UNIV OF CHEM TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com